SRR2016944
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- MYC_TARGETS_V2+0.490
- ANGIOGENESIS+0.390
- INTERFERON_GAMMA_RESPONSE+0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
- COAGULATION+0.250
- IL2_STAT5_SIGNALING+0.230
- KRAS_SIGNALING_DN+0.180
- MYOGENESIS+0.180
- ALLOGRAFT_REJECTION+0.170
Top 10 suppressed
- PROTEIN_SECRETION-0.520
- ANDROGEN_RESPONSE-0.390
- G2M_CHECKPOINT-0.340
- OXIDATIVE_PHOSPHORYLATION-0.320
- NOTCH_SIGNALING-0.300
- CHOLESTEROL_HOMEOSTASIS-0.270
- PI3K_AKT_MTOR_SIGNALING-0.270
- E2F_TARGETS-0.250
- MTORC1_SIGNALING-0.250
- FATTY_ACID_METABOLISM-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG585 | — | — | 0.839 |
| 2 | MDT-AP-1240 | Med | Medulloblastoma | 0.773 |
| 3 | TCGA-95-7944-01A-11R-2187-07 | — | cohortA1 | 0.752 |
| 4 | R79 | — | — | 0.750 |
| 5 | BS_77317DY4 | Med | Medulloblastoma | 0.748 |
| 6 | SRR12202481 | — | — | 0.739 |
| 7 | BS_G5QBBHDV | low-grade glioma | — | 0.730 |
| 8 | R117 | — | — | 0.722 |
| 9 | SRR25617829 | — | D | 0.720 |
| 10 | MNG1108 | — | — | 0.714 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.170 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.120 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| COMPLEMENT | 0.010 | Inavolisib | — uncovered |